Last reviewed · How we verify
0.25% ropivacaine epidural block
At a glance
| Generic name | 0.25% ropivacaine epidural block |
|---|---|
| Sponsor | China Medical University, China |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery (NA)
- Effects of Different Anesthetic Techniques on Intraoperative and Postoperative Pain Levels and Cognitive Function in Patients Undergoing Hepatectomy for Liver Cancer (NA)
- Minimally Invasive Esophagectomy Pain Control Trial (PHASE1, PHASE2)
- Regional Anesthesia Techniques in Breast Surgery (NA)
- Comparing Effectiveness of CSE Versus DPE for Labor Analgesia (PHASE4)
- Analgesic Efficacy of Ropivacaine Alone or in Combination With Adjuvants on Post-operative Analgesia Following Video-Assisted Thoracoscopic Surgery. (PHASE4)
- Quadratus Lumborum Block for Pediatric Hip Surgery (NA)
- TAP Block Versus Conventional Systemic Analgesia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 0.25% ropivacaine epidural block CI brief — competitive landscape report
- 0.25% ropivacaine epidural block updates RSS · CI watch RSS
- China Medical University, China portfolio CI